New anti-tuberculosis drugs in clinical trials with novel mechanisms of action
- 1 December 2008
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 13 (23-24) , 1090-1098
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- In Vitro Antimycobacterial Spectrum of a Diarylquinoline ATP Synthase InhibitorAntimicrobial Agents and Chemotherapy, 2007
- Location of Persisting Mycobacteria in a Guinea Pig Model of Tuberculosis Revealed by R207910Antimicrobial Agents and Chemotherapy, 2007
- Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB DrugsAntimicrobial Agents and Chemotherapy, 2007
- OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In MicePLOS Medicine, 2006
- Combinations of R207910 with Drugs Used To Treat Multidrug-Resistant Tuberculosis Have the Potential To Shorten Treatment DurationAntimicrobial Agents and Chemotherapy, 2006
- Combination Chemotherapy with the Nitroimidazopyran PA-824 and First-Line Drugs in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2006
- Genetic Basis for Natural and Acquired Resistance to the Diarylquinoline R207910 in MycobacteriaAntimicrobial Agents and Chemotherapy, 2006
- Mycobacterium tuberculosis Upregulates Coreceptors CCR5 and CXCR4 While HIV Modulates CD14 Favoring Concurrent InfectionAIDS Research and Human Retroviruses, 2006
- Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Mycobacterial InfectionsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Use of Transposon Tn 5367 Mutagenesis and a Nitroimidazopyran-Based Selection System To Demonstrate a Requirement for fbiA and fbiB in Coenzyme F 420 Biosynthesis by Mycobacterium bovis BCGJournal of Bacteriology, 2001